| Names | |
|---|---|
| Preferred IUPAC name | N-{2-[4-(acetylamino)phenoxy]ethyl}acetamide hydrochloride |
| Other names | Propacetamol HCl Pro-Dafalgan Proparacetamol Hydrochloride |
| Pronunciation | /prəʊˌpæsəˈmoʊl haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | 66532-86-5 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Propacetamol Hydrochloride**: ``` CCCC(=O)NC1=CC=C(C=C1)OC(=O)NCC2=CC=C(C=C2)Cl ``` This is the **SMILES** string representation used for JSmol/3D molecular visualization. |
| Beilstein Reference | 6351924 |
| ChEBI | CHEBI:75104 |
| ChEMBL | CHEMBL2104379 |
| ChemSpider | 157399 |
| DrugBank | DB09114 |
| ECHA InfoCard | 100.120.477 |
| EC Number | 25953-17-7 |
| Gmelin Reference | 89280 |
| KEGG | D05530 |
| MeSH | D017102 |
| PubChem CID | 146211 |
| RTECS number | UF9808000 |
| UNII | B2J233MYZK |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID80121684 |
| Properties | |
| Chemical formula | C13H21ClN2O4 |
| Molar mass | 302.79 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 0.62 |
| Acidity (pKa) | 10.3 |
| Basicity (pKb) | 10.51 |
| Magnetic susceptibility (χ) | -5.6e-6 |
| Refractive index (nD) | 1.572 |
| Dipole moment | 9.68 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 399.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -482.7 kJ/mol |
| Pharmacology | |
| ATC code | N02BE04 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07 |
| Pictograms | `"Acute toxicity, Health hazard, Exclamation mark"` |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P302+P352, P305+P351+P338, P332+P313, P337+P313, P362+P364 |
| Lethal dose or concentration | Lethal dose (LD50) (oral, rat): 600 mg/kg |
| LD50 (median dose) | 1,600 mg/kg (rat, intravenous) |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 1-2 g every 4-6 hours (max 8 g/day) |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Acetaminophen Paracetamol Phenacetin Propacetamol Acetanilide |
| Parameter | Details | Manufacturer Commentary |
|---|---|---|
| Product Name | Propacetamol Hydrochloride | In production documentation, the name Propacetamol Hydrochloride describes the mono-hydrochloride salt form of propacetamol, a paracetamol (acetaminophen) prodrug primarily formulated for parenteral administration. The product name used in batch manufacturing and QC aligns with the regulatory and pharmacopoeial nomenclature applied according to the intended market and registration jurisdiction. |
| IUPAC Name | 4-(Acetylamino)phenyl N,N-diethylglycinate hydrochloride | IUPAC designation provides the unambiguous chemical structure for regulatory compliance, technical references, and certificate of analysis production. IUPAC name is not typically used in internal batch records but is critical for new DMF filings and patent clarity. |
| Chemical Formula | C13H20ClN2O3 | The manufacturer assigns chemical formula according to the monohydrochloride salt, which includes the counter-ion. Quality release requires precise molar analysis and verification of salt formation in intermediate and final control steps. Any deviation in elemental composition flags the batch for deeper impurity analysis, especially for non-neutralized base forms or over-crystallization, which impact downstream stability and solubility. |
| Synonyms & Trade Names | Proparacetamol hydrochloride, Propacetamol HCl, Propacet hydrochloride | Synonyms predominantly reflect differences in region-specific naming conventions and trade registry decisions. Technical sales documentation and COA references will list synonyms for traceability. For US and EU markets, trade name protection and INN/USAN compliance drive labeling, but internal manufacturing documents default to the systematic or INCI name to avoid mislabeling risk. |
| CAS Number | 66532-86-5 | The CAS number uniquely identifies the monohydrochloride salt required for traceability throughout production, REACH registration, and DMF/CEP filings. Batch records include both the free base and salt CAS numbers when relevant for multi-stage synthesis tracking. Process risk evaluations typically assess cross-contamination and mislabeling prevention based on CAS-linked raw material management. |
| HS Code & Customs Classification | 2924.29 | The harmonized system code 2924.29 categorizes the compound under acyclic amides. Customs and import/export documentation mandate precise HS code assignment based on finished product form and purity claim. Discrepancies in HS code usage between jurisdictions can trigger regulatory holds; exporters maintain a concordance database to align with local tariff structures. Ongoing monitoring of international code updates by the regulatory department ensures continuous compliance. |
Industrial batches of Propacetamol Hydrochloride present as a solid, typically observed as a white to off-white crystalline powder in our facilities. Color and odor remain nearly neutral, but minor tonal variations may occur if raw material lots differ or if extended storage introduces trace impurities. Form and flowability can shift depending on particle-size distribution, which relates directly to downstream use—finer powders support rapid dissolution, while coarser grades may be needed for certain tablet formulations.
Melting behavior reflects product purity and crystal habit; multi-modal melting or discoloration on heating usually flags trace degradation or non-ideal crystallization conditions. Routine batch analysis includes observation of these transitions for early impurity screening. Boiling and flash points are not commonly referenced in handling Propacetamol Hydrochloride, given its decomposition prior to boiling. Density follows crystal form and is grade-specific, being checked for process calibration and blending calculations.
Batch stability in our production runs does not merely depend on the base chemical structure but also hinges on residual solvents, minor secondary products from synthesis, and exposure to moisture or heat during process interruptions. The compound resists hydrolysis under dry, controlled conditions, but the presence of water or basic pH accelerates breakdown, so environmental monitoring during storage and transport takes priority. Raw material upstream contaminants or improper purification can substantially impact batch reactivity.
Solubility responds to particle size, crystal form, and possible hydrate states. Technicians preparing solutions for analytical or downstream processing always assess dissolving time and clarity. Undissolved residues or slow dissolution can trace to inadequate milling or persistent insoluble process impurities, requiring adjustments in batch processing protocols.
Released lots adhere to defined purity levels and impurity thresholds tailored to customer specification or intended application, with pharmaceutical grades receiving the most stringent controls. For industrial, non-pharmaceutical grades, wider ranges may be permitted, especially on physical form and color.
Routine impurity profiles include process-related byproducts (acetaminophen, specific aryl amine derivatives) and residual solvents. Source control is critical; any new raw material supplier triggers a full impurity re-evaluation. Limits for each impurity get determined by the intended final use and national regulations.
Release testing follows either in-house validated HPLC methods or internationally accepted pharmacopoeial standards (if applicable). Test selection and pass–fail values are grade- and region-dependent; significant deviations prompt investigation and may require batch rework or rejection.
Manufacturing relies on the consistent supply of high-purity p-aminophenol, appropriate acylating agents, and qualified hydrochloric acid. Sourcing focuses on both purity and traceability since off-grade intermediates often introduce persistent impurities, complicating downstream purification.
Standard manufacture involves acylation of p-aminophenol with a suitable chloroacetylating agent, followed by neutralization and salt formation with hydrochloric acid. Continuous monitoring of pH and temperature ensures reproducibility. Selection of solvent system and reaction temperatures determines throughput and impurity fingerprint.
Key controls include stoichiometry, neutralization endpoints, and solvent removal rates. Crystallization steps require close temperature ramp control and agitation speed settings, as poor control leads to nonuniform crystals or occluded impurities. Purification uses multiple washing and recrystallization cycles, with targets set by downstream QC feedback concerning prior out-of-spec batches.
Final lots undergo independent batch assessment: identification, purity, moisture, and impurity profile. Release requires both analytical pass and process documentation completion, tying each lot number to post-process stability and impurity data.
Propacetamol Hydrochloride undergoes hydrolysis under alkaline or enzymatic conditions, yielding acetaminophen. This reaction is relevant in both pharmaceutical formulation and in toxicological evaluation. Understanding reactivity with excipients is vital during preformulation.
Modifications or downstream synthesis attempt require established conditions—controlled pH, polar solvents, moderate temperatures—careful choice of catalyst and reaction environment to minimize degradation and favor desired pathways. Any deviation may promote side reactions and unwanted impurity persistence.
Main downstream focus lies in prodrug or combination analgesic applications, with derivative selection tailored to pharmacological requirements. Research today explores further esters and mixed salt forms.
Long-term quality requires protection from ambient moisture, oxygen, and light. Degradation risk increases with humidity excursions, so climate-controlled storage, moisture barrier packaging, and light-blocking containers remain standard practice for our outgoing shipments.
Direct contact with reactive metals, basic plastics, or glass with flawed surface chemistry often causes trace contamination. Only chemically inert primary packaging receives internal approval. Selection trials involve accelerated testing for every packaging change.
Shelf life depends on adherence to recommended storage; visible yellowing, clumping, or off-odor signals advanced hydrolysis or contamination. Release specifications include periodic stability pulls, with real-time and accelerated degradation data logged for regulatory and customer traceability.
Workshops label all containers in alignment with classified irritant and acute toxicity signaling per local and international regulatory guidelines. Variations in cut-off values reflect regional interpretation of available toxicity data.
All personnel receive chemical safety training emphasizing dust management, respiratory protection, and skin contact avoidance. Production spaces use local exhaust ventilation and closed transfer systems where dusting risk exists.
Toxicological review draws on compound-specific literature and batch-derived impurity assessment; safety teams define SOPs for handling, exposure, and incident response using latest workplace hygiene data. Permissible exposure levels conform to the lowest published standards where available, updated as new regulatory or scientific data emerges.
In actual industrial-scale manufacturing of Propacetamol Hydrochloride, available output reflects multiple factors: upstream raw material supply certainty, reactor and purification train capacity, batch scheduling, and annual maintenance outages. Output levels are generally tiered by product grade and the intended pharmaceutical or research application. Shifts in export logistics or regional market priorities directly affect short- and mid-term supply. During periods with constrained raw acetaminophen or capping reagent availability, plant throughput decreases, and available contractual volumes are reallocated toward established buyers with annual offtake agreements.
Typical production lead times reflect grade, packaging type, and plant schedule. Standard grades for formulation or compounding use usually ship within several weeks of order confirmation and receipt of purchase terms. MOQ is dictated by validated packaging lines, logistics planning, and customer compliance requirements. For domestic or regular international buyers specifying standard packaging, MOQ reflects a single full pallet/lined drum load. Custom packs or specialized certifications may require a higher MOQ due to line changeover and additional quality checks.
Selection covers: fiber drums with liner, polyethylene bags within outer drums, double-lined antistatic bags for moisture-sensitive applications, or tamper-evident container-sealed packs for higher-grade requirements. Pharmaceutical buyers often specify secondary containment or batch-specific labeling. Each option is validated for batch traceability, contamination prevention, and regulatory audit trails. Package selection impacts both allowable batch size and final moisture/purity stability during distribution.
Bulk contracts typically use FCA or FOB incoterms, reflecting plant-to-port loading logistics and buyer’s import requirements. Smaller lots or research quantities may ship via express airfreight, fully documented with COA and complete regulatory trace pack. Payment terms vary by buyer history, creditworthiness, and relationship maturity, with L/C or prepayment predominating for first-transaction customers. Delayed payment is rare except for top-ranked pharmaceutical clients with validated credit control.
Cost structure draws heavily from acetaminophen intermediate markets and the capping agent’s commodity price, as well as the availability of pharmaceutical-grade reagents. Unplanned outages, upstream plant incidents, and regulatory-enforced production pauses (notably in CN and IN) drive cost volatility. Trucking, energy, and compliance costs tie directly to site location and local regulation stringency. Purification and isolation steps for higher-grade material create step increases in direct labor, solvent, and waste management costs.
Pricing diverges sharply by grade: pharmaceutical vs. non-pharmaceutical, release specification (EP, USP, JP), batch-to-batch impurity limits, and special-packaging requests. Higher assay purity, lower residual solvent, and well-documented impurity profiles carry premium prices. Regulatory audits and documentation requirements increase compliance costs, reflected in pricing surcharges, especially for buyers needing full QP documentation or repeat testing protocols.
Cost per kilogram increases for smaller packs due to added material, labor, and documentation needs. Buyers requesting GMP-certified, cGMP-audited, or custom-labeled shipments absorb downstream process and certification costs that do not appear in standard bulk drums.
Market liquidity remains spotty outside regulated pharmaceutical channels. US, EU, JP maintain tight controls on imports, audit oversight, and distributor traceability. In CN and IN, supply responds more rapidly to upstream cost swings but is susceptible to regulatory-driven shutdowns and shifting government priorities. Short-term variance in trade policy, port conditions, or health emergencies spikes demand and strains logistics.
US buyers focus on DMF-holder status and NDA-backed supply relationships. EU procurement strictly audits for GMP process data, impelling local QP or batch-release testing. JP requires localized regulatory documentation and direct testing for batch-specific comparability. IN and CN markets respond quickly to price but face stiffer batch-to-batch QC enforcement if targeting regulated export markets. Availability or price outliers usually originate from disruptions in CN or SE Asia raw material trade, with ripple effects into end-user pricing worldwide.
Into 2026, margin pressure from raw material volatility, ongoing environmental policy in Asia, and persistent inflation in global logistics likely sustain a higher pricing baseline. Growth in regulated pharmaceutical consumption may tighten supply in US/EU/JP, leading to prolonged spot price spreads versus unregulated markets. Downward price movement requires consistent improvement of upstream raw material availability or breakthrough improvements in solvent recycling and batch purification efficiency.
Forecasting draws data from plant production records, shipment logs, market procurement trends (via proprietary internal and industry association sources), and post-shipment feedback on compliance and recall incidents. External sources include customs billing where available, monthly API pricing reports, and regulatory notice bulletins in each monitored economy.
Recent production adjustments stem from periodic raw acetaminophen shortages and short-term local production curtailments tied to regulatory review cycles. New guidance on excipient impurities and solvent residue testing, especially within EU and US, increases documentation and lot testing requirements for pharmaceutical-grade buyers.
Shift in regional GMP enforcement (with IN and CN stepping up plant inspection frequency in 2023–2024) has driven some consolidation in smaller manufacturers, particularly those lacking full trace and impurity management. EU regulators have signaled tightening validations for nitrosamine risk, likely increasing the cost and time to release for new batches.
Technical teams have deepened scrutiny on raw supplier qualification, started dual-sourcing strategies for volatile intermediates, and invested in solvent recycling to cut costs. Batch control is reinforced with more frequent in-process checks and release assays, especially for lots targeting regulated markets. Some production is held in quarantine pending full regulatory sign-off or unexpected market-driven specification changes.
Propacetamol Hydrochloride serves as a parenteral analgesic intermediate. Its most common use lies in hospital and clinical settings for rapid pain management, where intravenous administration is essential. Pharmaceutical production environments also handle this compound during the manufacture of finished propacetamol dosage forms or as part of contract manufacturing processes.
Manufacturers of injectables demand strict batch consistency to ensure predictable dissolution rates and low particulate levels, as downstream filtration and sterile processing provide little opportunity to resolve raw material variability. In API synthesis sectors, the focus remains on chemical purity and absence of process-derived impurities, minimizing risk to the final formulation and avoiding scrutiny in regulatory filings.
| Application | Preferred Grade | Key Grade-Dependent Parameters |
|---|---|---|
| Intravenous Pharmaceutical Products | Parenteral / Pharmaceutical Grade (GMP) | Purity profile, residual solvents, endotoxin levels, visible and sub-visible particulate control |
| API Intermediate Synthesis | Technical Grade / Custom Specification | Chemical purity, control over identifiable starting materials, residual byproduct validation |
| Formulation Research, Pilot Plant Trials | R&D/Laboratory Grade | Representative batch data, impurity profile, feasibility sample for process simulation |
End-user application determines parameter prioritization. Companies sourcing for injectable-grade applications focus heavily on specified purity ranges and very tight control over pyrogen levels, since downstream sterilization may not remove pre-existing endotoxins. For technical-grade input, research teams emphasize predictability in reactivity and minimal unknown contaminants so downstream process efficiency is not affected.
Lot-to-lot consistency matters most for pharmaceutical formulation. Inconsistent properties such as moisture content, particle size, or solvent residue can complicate scale-up and may trigger regulatory concerns if uncontrolled deviations appear in audit trails. Technical supply contracts often mandate ongoing analytics to pre-empt raw material variability before production milestones.
Determine the end-use—whether for a finished parenteral drug, an API intermediate, or non-clinical research. This clarifies the baseline required for physical and chemical quality, processability, and cGMP compliance.
Evaluate the applicable pharmacopeial or agency standards for the destination market. Injectable and human-use applications normally trigger much stricter regulatory scrutiny, and document trails (such as DMFs or CEPs) may be required for downstream regulatory filings.
Decide on acceptable ranges for principal assay, starting material residues, byproduct profile, and process impurities. Manufacturing processes using recycled solvents, or alternative synthesis routes, often call for tailored impurity controls due to variable feedstock origins. Many customers initiate technical discussions to align supplied grade specifications with the intended use, especially in multi-national operations with diverse legal frameworks.
Assess intended batch size and cost targets in light of plant capacity, minimum order quantities, and sampling logistics. Price disparities often reflect both material purity demands and the intensity of post-synthesis purification. Pharmaceutical-grade lots require extended hold times for batch release due to more extensive quality checks, which can affect both lead time and final pricing.
Request a representative lot sample for method development, process fit trials, or compatibility studies. This step allows direct validation of material performance under actual process conditions. Typically, the manufacturer supplies full batch traceability, CoA, and recent analytical data. Sample validation provides a critical check against unexpected changes in impurity profiles due to manufacturing scale-up or process modifications between orders.
In our production facilities, all processes adhere to established pharmaceutical GMP and ISO 9001-based quality systems. Internal audits focus sharply on incoming raw material traceability, in-process consistency, and end-product traceability. Production records are maintained for every batch, supporting complete backward investigation capability during quality reviews or customer audits. The strength of a certification framework is measured not only by the presence of certificates but by the rigor of process validation, change control, and deviation management practices, which directly affect batch-to-batch reliability. Audit findings drive ongoing improvements, with corrective actions logged into a closed-loop management system. Auditable documentation and controlled calibration of critical testing equipment ensure confidence in every reported result.
Propacetamol Hydrochloride is supplied according to documented specifications, with grades differentiated by application sectors—typically pharma, veterinary, or research grade on customer request. Certification often includes a certificate of analysis referencing analytical data for each lot, and release criteria reference internal QC protocols aligned with regional pharmacopeial standards when applicable. Regulatory support documentation, such as Drug Master Files (DMF) for designated markets, is provided when required and subject to update cycles and authority requests. Compliance with specific monographs depends on end-use markets and must be designated at inquiry.
Each consignment includes traceable documentation: batch records, test results, and CoA with analytical details verifying identity, content, and relevant impurities. Full traceability to process lot and raw material sources simplifies customer regulatory submissions and post-market surveillance. For export markets, supplemental dossiers may be supplied upon request, typically including stability data, route-specific impurity profiles, and, where agreed, process validation summaries. GMP compliance evidence is frequently maintained for customer inspection; on-site audits are welcomed where appropriate and scheduled to match operational workloads.
Long-term partnerships depend on reliable production and transparent communication. We reinforce production stability through forecasting agreements, safety stock buffers, and scheduled preventative maintenance on key production lines. Monthly output volumes are discussed based on actual demand visibility, with priority capacity allocation set for contracted partners. For larger or unpredictable projects, short-lead negotiation is possible, supported by diversified sourcing of critical raw inputs. Customers with variable demand can request flexible delivery scheduling—split shipments, lot reservations, or expedited release cycles—according to mutual planning periods.
Capacity utilization is managed by batch campaign planning based on equipment qualification status and raw material availability. Production batches are scaled according to current order demand and process optimization data. For each grade, batch sizes are optimized by targeted impurity thresholds and intermediate hold times. Major control points during synthesis minimize byproduct accumulation, and in-process testing addresses both content and impurity drift. Batch-to-batch reproducibility is tracked using statistical process control, with any parameter drift leading to corrective action or process re-optimization. Long-term supply assurances rely on dual-site capacity where operationally justified and raw material dual-sourcing per criticality review.
Samples are dispatched upon verified inquiry and intended use declaration. Selection of the appropriate grade or compliance standard—pharma, veterinary, or customized analytic criteria—ensures relevant testing for customer comparison. Each sample set includes batch reports, recent CoA, and analytic methodology summaries. For specialized project requirements, our team coordinates sample selection from recent campaigns matching as closely as possible the final intended supply grade. Response times and sample volume depend on the current production schedule and regulatory requirements of the receiving country.
For project-based or development-stage customers, contract manufacturing and supply terms are set according to developmental timelines and technical stages. Flexible order quantities, campaign-synchronization, and rapid technical support are negotiated case by case. For multi-region projects, we align release documentation and supply strategy with each end-market’s regulatory and shipment requirements. Short or trial production runs receive the same process controls as large campaigns, but with added coordination between technical, QC, and logistics teams to manage faster feedback cycles and tight change control.
| Procurement Support Feature | Manufacturer-Driven Advantage |
|---|---|
| Quality Certification & Audit Support | Direct access to facility documentation, process validation, and audit follow-up reports increases buyer confidence before large orders. |
| Batch Inspection & Release | Manufacturer batch release criteria reflect both process capability and customer-specific requirements, not generic market standards. |
| Documentation Package Customization | Technical reports provided according to customer regulatory filing needs, not static templates. |
| Capacity Flexibility | Production batches planned in advance to buffer against demand volatility, supported by manufacturer-level raw material contracting. |
| Process Transparency | Full supply chain and process data available for customer validation and regulatory submissions upon established confidentiality terms. |
R&D teams focus heavily on improving synthesis efficiency and impurity control during the production of propacetamol hydrochloride. Direct acetylation methods of active intermediates receive increased attention for reducing solvent consumption and unnecessary by-products. Process engineers experiment with various catalysts and workflow designs to achieve higher conversion yields and cleaner crystallization, which directly affect the cost structure and waste profile. Analytical departments now lean on advanced chromatographic techniques to characterize and minimize trace impurities—especially those with regulatory concern for genotoxic potential.
Another trending area involves particle size and polymorph control in response to customer requirements in formulation. Customers requesting injectable or fast-release applications demand particle size distributions tailored for specific dissolution characteristics. R&D groups collaborate with formulation specialists to pinpoint how physiochemical properties impact downstream performance, especially for injectable grade material.
Traditionally supplied to oral and parenteral drug manufacturers, propacetamol hydrochloride increasingly draws interest from pediatric and geriatric dosage developers, attracted by the product's rapid conversion to paracetamol in vivo. An uptrend in demand for combination therapies and co-formulation with other analgesics is noted, requiring compatibility studies and stability investigations. Demand from global markets with stricter contaminant limitations has also pushed more requests for customized grades with narrower specification profiles.
Reducing synthesis-related impurities remains a technical challenge, as by-product profile changes based on the raw material route and processing conditions. Close cooperation between production and quality teams is essential to trace impurity sources—especially nitrosamines and chlorinated by-products linked to raw material quality. Continuous flow synthesis trials have seen moderate success in pilot settings, offering improved thermal control and scalability, but integration into full-scale production depends on long-term reliability and cost outcomes. Energy optimization during purification steps is another active pursuit, as solvent selection and recycling loops offer clear operational benefits while requiring careful validation for drug product compliance.
Global demand for propacetamol hydrochloride tracks closely with the expansion of healthcare infrastructure in developing economies and the regulatory push for safer parenteral analgesics. Market signals point to steady volume growth over the next three to five years, driven by higher adoption rates in hospital settings and increased generic drug registrations. Stringent quality and trace impurity standards in regions such as Europe and North America continue to raise the barrier for entry, pushing investment in analytical and process innovation.
Manufacturing lines are shifting towards safer, closed-system processes to minimize operator risk and reduce cross-contamination. Controlled crystallization and real-time monitoring of critical process parameters gain prominence, as customers demand narrower specification windows for sensitive formulations. Integration of real-time release testing for key attributes marks a substantial evolution, helping shorten batch release cycles and streamline supply chain reliability.
Sustainability efforts target waste minimization and energy footprint reduction throughout the propacetamol hydrochloride synthesis chain. Solvent recovery strategies and modular water treatment for effluent streams remain active projects. Teams assess lifecycle impacts of various raw material routes, prioritizing methods that avoid problematic reagents and promote atom economy. The drive for green credentials leads to a preference for continuous process design and real-time pollution control measures at each production node.
Technical teams provide direct support during analytical method establishment, impurity profiling, and process validation as customers implement the material into new or existing dosage forms. Close feedback loops with R&D allow rapid adaptation if specification challenges arise in scaling up or in regional compliance checks. Questions concerning solvent residues, stability issues under forced conditions, or particle property adjustments routinely receive in-depth technical review before solution proposals are given.
Every customer formulation presents unique processing needs, particularly for injectable and fast-dissolving formats where propacetamol hydrochloride grade—particle size, residual solvents, and water content—plays a critical role in performance. Application engineers offer recommendations for storage, handling, and blending based on observed experience across different grades. Assistance includes troubleshooting filtration or dissolution issues at point of use, with tailored advice depending on batch consistency, storage environment, and formulation sensitivity.
After-sale support continues through full batch lifecycle, with retained sample analysis and quality feedback, supporting customer investigations of any observed anomalies or out-of-spec events. Complaint management adheres to documented investigation procedures, with cross-functional input from quality, production, and R&D departments. Ongoing commitment to regulatory information updates ensures that any changes in guideline interpretations or impurity concerns are proactively communicated to partners using propacetamol hydrochloride in regulated markets.
We run a dedicated manufacturing facility that produces propacetamol hydrochloride at industrial scale. Our reactors, purification systems, and filtration lines handle large batch runs, giving us visibility and control over every input and process variable. Skilled plant operators monitor all key points—from solvent selection through to crystallization and drying—ensuring that the material meets process requirements batch after batch.
Pharma companies rely on propacetamol hydrochloride as a vital intermediate for injectable and oral analgesic formulations. Our output suits bulk formulation lines where hydrolytic stability and precise salt composition support downstream processing. Strong reproducibility in particle flow and moisture content serves high-speed tabletting and sterile packaging setups. Process engineers implementing continuous manufacturing can depend on a consistent feedstock profile.
Product consistency starts with raw material traceability. We vet all raw inputs ourselves against analytical benchmarks and maintain online monitoring throughout synthesis and purification. Each batch undergoes chromatographic and spectrometric checks on-site, targeting both purity and residue profile thresholds. Documentation aligns with current regulatory guidelines and is always available on request.
We run automated filling and sealing systems capable of palletizing multiple packaging formats—fibre drums, lined cartons, and specialty barrier options for moisture-sensitive consignments. Our finished goods warehouse holds buffer inventory so we can fulfill scheduled orders and urgent replenishment without production delays. Load planning for full-container shipments takes place based on real production outputs, not third-party allocation.
Our technical team includes engineers and chemists who work directly with partners on process integration. If process modifications are required, our support staff address technical queries relating to material handling, solubility curves, or formulation compatibility using data drawn from our own pilot lines and analytical labs. We provide detailed product validation dossiers so your regulatory, quality, and R&D teams have the insight needed to complete their process reviews. Customization options, such as granulation and particle sizing, are available for industrial-scale collaboration.
Managing direct production enables us to commit to timeline certainty and order flexibility. Manufacturers benefit from transparent production windows and direct shipment alignment with their batch planning. Distributors working to regulatory deadlines receive consistent grade and specification—reducing downstream qualification time. For procurement teams, long-term purchasing draws from production capacity—not from speculative or intermediary inventory—which lowers sourcing risk. Our documentation supports compliance reviews and tender applications across regulated and emerging markets.
Each delivery of propacetamol hydrochloride comes from an integrated production line, backed by real-time QA and direct-to-client supply control. Our factory team addresses process and compliance challenges with practical experience drawn from hands-on manufacturing. These factors drive reliability for industrial buyers who operate in strictly regulated or time-sensitive markets.
Our production lines have handled propacetamol hydrochloride in bulk quantities for over a decade, supporting both research and large-scale pharmaceutical formulation. Out on the factory floor and within our quality labs, we experience firsthand how this compound behaves—from its hygroscopic traits to its reactivity with water and other excipients.
The appearance of propacetamol hydrochloride should remain a white to slightly off-white crystalline powder at our stated purity levels. Any deviation often signals a problem—moisture exposure, improper storage, or contamination during packaging. Our controlled environment production areas stay below 60% relative humidity to manage this risk. Each batch receives regular moisture content analysis using Karl Fischer titration, ensuring our deliveries always meet pharmacopoeial requirements.
Propacetamol hydrochloride dissolves quickly in water, producing a clear solution. This high aqueous solubility plays a crucial role in both injectable and oral formulations, greatly simplifying dosing accuracy and content uniformity on a manufacturing scale. We keep close tabs on the pH of aqueous solutions, observing that a freshly prepared solution falls between 3.5 and 4.5, depending on batch and water quality. Consistent pH is essential; deviations hint at impurity or hydrolysis, raising red flags during quality assurance sampling.
Our team addresses stability more proactively than most. Propacetamol hydrochloride resists oxidation under normal atmospheric conditions, but its ester functional group shows sensitivity to hydrolysis, especially in the presence of moisture. Short-term exposure often escapes without serious impact, but over weeks, humidity breaks down the molecule, yielding paracetamol and diethylglycine—both detected using HPLC in our analysis lab. We use double-wall polyethylene drums with high-integrity tamper-proof seals, minimizing direct contact with air and water vapor in transit and storage.
Temperature maintenance is another key requirement. We avoid fluctuations: our dispatch warehouses and refrigerated storage never exceed 25°C. This slows potential hydrolytic degradation and extends shelf life. Every long-term batch stability study we perform supports this with consistent assay results and negligible byproduct formation under these conditions.
Formulators working with propacetamol hydrochloride must watch for basic or alkaline excipients, which can accelerate ester breakdown. Microcrystalline cellulose, starch, and common sugar alcohols show compatibility in our trials, but we avoid mixing with calcium carbonate, magnesium stearate, and other basic powders if water is present. Our technical support team regularly helps clients evaluate pilot-scale blends to avoid time-consuming granulation failures downstream.
Sterile liquid preparations, such as injectable solutions, demand the highest vigilance. Even minute levels of trace metals or base residues in water for injection will catalyze hydrolysis. We manufacture our injectable-grade product using extra purification steps and monitor finished product stability for at least 12 months to back up our recommended shelf life.
Direct manufacturing involvement gives us unique insight into troubleshooting formulation issues with propacetamol hydrochloride. By maintaining careful control of moisture and temperature, verifying solubility and pH, and avoiding incompatible excipients, development teams maximize stability and performance in finished products. Our dedicated technical team is available to review formulation projects, share sample QC results, and offer practical advice tailored to specific scale-up challenges.
From our ongoing experience in the bulk manufacture of propacetamol hydrochloride, production scale directly influences both minimum order quantity (MOQ) and lead time. Across our main facility, production is set up for industrial-scale API manufacturing, allowing us to deliver commercial lots with consistent batch quality. Our typical MOQ aligns with optimized batch cycles: a standard MOQ remains at 100 kg, designed not just for logistics but to maintain reliable chemical uniformity from batch to batch.
Consistent supply rests on raw material readiness and efficient factory scheduling. Our teams source key intermediates globally, with raw material contracts reviewed quarterly to avoid disruptions. Propacetamol hydrochloride synthesis, as a multi-step API process, requires careful reactor loading, in-line monitoring, and quality assurance during each batch. Incorporating stringent GMP controls means batch records, in-process control, and finished product testing all lengthen the timeline versus basic commodity chemicals.
Based on these factors, our standard lead time for bulk orders averages 4-6 weeks from contract to delivery readiness. This window allows raw material QC, production slot allocation, the multistep synthesis, downstream workup, and analytical release. For repeat clients or standing orders, lead times often reduce by up to a week, as our production team gains forecast visibility. In cases of urgent demand, expedited scheduling is possible, but it places extra demands on supply chain and production line which may involve a premium allocation cost.
Our standard bulk packaging for API propacetamol hydrochloride focuses on safe transit and minimizing contamination risk. Drums range from 25 kg to 50 kg each, using double-sealed PE liners and tamper-evident closures. For exports or cold chain shipping, additional measures such as full palletization, desiccant control, and reinforced liners support integrity from dock to destination. All shipments include a complete documentation set—certificate of analysis, batch record, MSDS, and transport documents—prepared by our QA release team and available in both hard copy and digital formats.
Over the past decade, customer needs have shifted to include not just larger volume orders, but also requests for shorter timelines and bespoke packaging. Our engineering staff continuously reviews bottleneck steps in synthesis and downstream processing to cut cycle time—such as solvent recovery optimization or automated batch charging. For select long-term partners, we offer production slot reservation to guarantee both timing and priority for sensitive or high-volume projects.
Meeting bulk procurement requirements for propacetamol hydrochloride is much more than a numbers game. MOQ and lead time reflect the realities of factory process, rigorous QC, and international transport. Reliable delivery comes through close coordination between our supply chain, plant scheduling, lab analysis, and logistics teams. Our approach remains straightforward: set MOQs to protect production consistency, maintain enough capacity to adapt to shifting market demand, and keep clients fully informed through each step of the order cycle. We provide detailed technical and quality documentation for every order, and our team stands ready to support both standard and urgent requests directly from the manufacturing floor.
Producing Propacetamol Hydrochloride at industrial scale comes with responsibility for more than just chemistry and batch consistency. Every time we prepare a shipment for international clients―whether API procurement specialists or multinational formulators―our technical and regulatory team faces a demanding landscape of import/export requirements.
Many associate strict controls with narcotics or psychotropics. Yet, various governments classify key pharmaceutical intermediates according to their public health policies. Our direct experience confirms that Propacetamol Hydrochloride seldom appears on global “controlled drug” lists. Unlike raw paracetamol or acetaminophen, its classification remains ambiguous in several markets. This does not translate to relaxed scrutiny. Customs authorities in Europe, China, the US, and Middle Eastern countries routinely request detailed documentation. We furnish full certificates of analysis, manufacturing licenses, GMP documentation, and MSDS every time we handle international deliveries.
Batches leaving our site never rely on a single regulatory template. Our regulatory team evaluates the destination country’s current requirements for APIs, intermediates, excipients, and non-listed pharmaceuticals. For Propacetamol Hydrochloride, regulators may request import permits, end-user declarations, and confirmation of use in pharmaceutical production. For example, Asian and EU regulators commonly inspect both material origin and intended application, seeking to prevent diversion toward non-medical use. Our documentation and internal auditing integrate these realities. Failing to comply with an end-user certificate or omitting a technical data sheet nearly always results in border delays or complete rejection by customs.
Our supply chain avoids risk by using direct shipment or pre-cleared distribution points, only after negotiating correct HS codes and import classification. Propacetamol Hydrochloride’s customs code generally aligns under “pharmaceutical chemicals,” yet officials can interpret import duty and VAT status based on documentation quality and accuracy. Any error exposes our clients and us to compliance investigations.
Countries modify their lists of regulated substances without industry-wide announcements. We continually monitor legislative bulletins, customs notifications, and health authority guidelines. Our policy requires written confirmation of compliance before labeling and packing any Propacetamol Hydrochloride shipment for offsite transport. For years, major ports and airports have reviewed our packages for adherence to IATA, IMDG, or ADR guidelines even when Propacetamol Hydrochloride holds a low hazard classification under GHS or CLP. The prudent move: treat every shipment as subject to full pharmaceutical scrutiny.
Our factory never releases Propacetamol Hydrochloride without verifiable documentation in line with international standards. Regular training keeps warehouse and logistics staff informed about classification updates and geopolitical changes impacting cross-border trade. Should a client need specialized packaging or requires cold chain solutions, we design our logistics accordingly to meet both quality and compliance expectations. Large volume shipments, pilot samples, and regulatory reference batches all move through traceable, auditable channels. Our technical and legal teams collaborate on pre-shipment notifications if required by destination authorities.
ConclusionShipping Propacetamol Hydrochloride involves far more than arranging freight. Every export event draws on a blend of up-to-date regulatory intelligence, close contact with customs, and a disciplined approach to documentation. As a manufacturer, we take these steps not simply to move product, but to protect the integrity of the pharmaceutical supply chain worldwide.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
